Our Take
Crowley's framing of biotech as national security is sound; his actual policy asks (FDA trial reform, AI accessibility) are structural and real; but 'man-made problems' rhetoric sidesteps the harder truth that small biotech has always faced a brutal funding gauntlet and no regulation fix alone will close that.
Why it matters
U.S. biotech competitiveness is not just market share—it shapes drug supply chains, manufacturing capacity, and which nations lead in gene therapy and synthetic biology. Crowley's voice carries weight because BIO represents both startups and pharma, and his diagnosis of regulatory drag resonates across the industry, even if the cure is incomplete.
Do this week
Biotech founders and R&D leaders: audit your Phase II-III trial design this quarter against FDA Project Trailblazer guidelines and flag which bottlenecks are regulatory versus resource-driven, so you can separate real opportunity from unfounded hope.
Crowley calls for FDA modernization and AI democratization
John Crowley, CEO of the Biotechnology Innovation Organization (BIO), addressed approximately 20,000 attendees at the 2026 BIO International Convention in San Diego on the need for industry modernization. His core argument: clinical trial regulations, rising development costs, and unequal AI access threaten U.S. biotech leadership in a global market increasingly shaped by China's strategic investments.
Crowley praised the FDA's Project Trailblazer initiative to streamline experimental therapy testing, calling for continued modernization while keeping the FDA as the world's regulatory standard. He described BIO's work with regulators and industry stakeholders to identify development bottlenecks and proposed reforms to streamline trial approvals and accelerate regulatory review.
On artificial intelligence, Crowley identified a stark disparity: large pharmaceutical companies field hundreds of AI specialists, while small and mid-sized biotech startups lack equivalent resources. He framed this as a strategic vulnerability. "It's a challenge," he said, "because in our industry we work on such long timelines. An entrepreneur invested years to reach Phase III, and suddenly there's this massive disruptive technology." Crowley positioned BIO as the leader to accelerate AI implementation across drug development, clinical trials, and regulatory review.
Crowley's most emphatic message centered on competition with China, which has designated biotechnology a strategic priority through national development plans and invested heavily in research infrastructure and manufacturing. He argued that the most effective U.S. response is not isolation but improving domestic innovation ecosystem competitiveness. He repeatedly emphasized what he called "man-made problems," framing regulatory complexity, insufficient research funding, delayed patient access, and rising out-of-pocket costs as addressable policy failures.
The real argument is systemic, not just regulatory
Crowley's personal history shapes his credibility here. He co-founded Novazyme Pharmaceuticals after his two children were diagnosed with a rare muscular dystrophy, struggled to secure early funding, and saw his company acquired by Genzyme for $225 million one year after launch. He knows both the grassroots startup model and the brutal access problem.
His diagnosis on clinical trials has empirical backing: trial costs, site recruitment, and regulatory review cycles have ballooned. Project Trailblazer is a real attempt to address this. His concern about AI access is also grounded: startups cannot match big pharma's engineering depth, and delays in adoption could widen the capability gap.
What Crowley does not emphasize is that the "man-made problems" framing has limits. Even modernized trials require capital. Early-stage biotech funding is constrained not just by regulation but by limited risk tolerance among institutional investors. Small biotech always has been, and likely will remain, a high-friction journey. Regulatory relief helps at the margins but does not solve the underlying fundraising gauntlet he himself faced in 2000. Crowley solved his problem not through policy change but through credit card advances and home equity.
His point about China is strategically sound: biotech manufacturing capacity and research infrastructure matter. But he stops short of naming the harder question: whether U.S. policy can sustain innovation investment at the scale China is deploying without restructuring the entire funding ecosystem, not just the approval process.
What to watch
FDA Project Trailblazer is concrete. Startups and established biotech should track which trial design reforms actually ship and which remain aspirational. The regulatory modernization will matter most for Phase II-III programs where trial cost and timeline are already material drags.
On AI, Crowley's call for democratization is important but unspecified. Watch whether BIO convenes vendors and startups to define which AI tools (drug discovery, patient recruitment, safety monitoring) are actually accessible to teams of 10 to 50 people. Generic "AI access" statements will not shift behavior. Specific tool partnerships and pricing tiers will.
China's biotech investments are accelerating. U.S. competitiveness will depend on whether the domestic ecosystem can sustain continuous funding and talent flow, not just reduce friction at the regulatory gate.